Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.3
1.9
Journals
Tomography
Special Issues
Advances of PET-CT Imaging in Oncology
share announcement

Advances of PET-CT Imaging in Oncology

A special issue of Tomography (ISSN 2379-139X). This special issue belongs to the section "Cancer Imaging".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 6996

Special Issue Editor

Dr. Gaetano Paone

E-Mail Website
Guest Editor
Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland
Interests: PET/CT; hybrid imaging; theragnostic; therapy monitoring based on PET criteria; functional PET parameters; personalized dosimetry

Special Issue Information

Dear Colleagues,

Over the last decade, molecular imaging has remarkably improved the monitoring and management of oncological patients. In particular, PET-CT is a sensitive imaging modality that represents one of the pillars of molecular imaging in oncology, and has become fundamental for response evaluation in several tumor types. We are entering an exciting new era where innovations in PET-CT may bring new clinical opportunities and therapeutic strategies.

This Special Issue aims to summarize the most promising clinical applications and improvements in PET-CT imaging. Original research articles and reviews with particular interest in PET-based treatment response and PET applications in the theragnostic field are welcome, emphasizing (but not limited to) the present and future role of PET-CT imaging in prognosis, treatment response and disease relapse in oncology.

We look forward to receiving your contributions.

Dr. Gaetano Paone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tomography is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PET/CT
  • treatment response
  • oncology
  • theragnostic

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 4969 KiB  
Article
Integrated Small Animal PET/CT/RT with Onboard PET/CT Image Guidance for Preclinical Radiation Oncology Research
by Xinyi Cheng, Dongxu Yang, Debabrata Saha, Xiankai Sun and Yiping Shao
Tomography 2023, 9(2), 567-578; https://doi.org/10.3390/tomography9020046 - 04 Mar 2023
Cited by 1 | Viewed by 1916
Abstract
We have integrated a compact and lightweight PET with an existing CT image-guided small animal irradiator to enable practical onboard PET/CT image-guided preclinical radiation therapy (RT) research. The PET with a stationary and full-ring detectors has ~1.1 mm uniform spatial resolution over its [...] Read more.
We have integrated a compact and lightweight PET with an existing CT image-guided small animal irradiator to enable practical onboard PET/CT image-guided preclinical radiation therapy (RT) research. The PET with a stationary and full-ring detectors has ~1.1 mm uniform spatial resolution over its imaging field-of-view of 8.0 cm diameter and 3.5 cm axial length and was mechanically installed inside the irradiator in a tandem configuration with CT and radiation unit. A common animal bed was used for acquiring sequential dual functional and anatomical images with independent PET and CT control and acquisition systems. The reconstructed dual images were co-registered based on standard multi-modality image calibration and registration processes. Phantom studies were conducted to evaluate the integrated system and dual imaging performance. The measured mean PET/CT image registration error was ~0.3 mm. With one-bed and three-bed acquisitions, initial tumor focused and whole-body [18F]FDG animal images were acquired to test the capability of onboard PET/CT image guidance for preclinical RT research. Overall, the results have shown that integrated PET/CT/RT can provide advantageous and practical onboard PET/CT image to significantly enhance the accuracy of tumor delineation and radiation targeting that should enhance the existing and enable new and potentially breakthrough preclinical RT research and applications. Full article
(This article belongs to the Special Issue Advances of PET-CT Imaging in Oncology)
►▼ Show Figures

Figure 1

14 pages, 1187 KiB  
Article
Relationship between Baseline [18F]FDG PET/CT Semiquantitative Parameters and BRCA Mutational Status and Their Prognostic Role in Patients with Invasive Ductal Breast Carcinoma
by Francesco Dondi, Domenico Albano, Pietro Bellini, Luca Camoni, Giorgio Treglia and Francesco Bertagna
Tomography 2022, 8(6), 2662-2675; https://doi.org/10.3390/tomography8060222 - 27 Oct 2022
Cited by 1 | Viewed by 1667
Abstract
Aim: To assess the relationship between [18F]FDG PET/CT, breast cancer gene (BRCA) status, and their prognostic role in patients with ductal breast cancer (DBC). Methods: Forty-one women were included. PET/CT semiquantitative parameters such as standardized uptake value (SUV) body weight max [...] Read more.
Aim: To assess the relationship between [18F]FDG PET/CT, breast cancer gene (BRCA) status, and their prognostic role in patients with ductal breast cancer (DBC). Methods: Forty-one women were included. PET/CT semiquantitative parameters such as standardized uptake value (SUV) body weight max (SUVmax), SUV body weight mean (SUVmean), SUV lean body mass (SUVlbm), SUV body surface area (SUVbsa), metabolic tumor volume (MTV), total lesion glycolysis (TLG), ratio SUVmax/blood-pool (S-BP), and ratio SUVmax/liver (S-L) were also extracted. The relationship between these parameters, BRCA, and other clinicopathological features were evaluated. Kaplan–Meier, univariate, and multivariate analyses were performed to find independent prognosticators for progression free (PFS) and overall survival (OS). Results: Significant positive correlations between BRCA status and SUVmax (p-value 0.025), SUVlbm (p-value 0.016), and SUVbsa (p-value 0.018) were reported. Mean PFS was 53.90 months with relapse/progression of disease occurring in nine (22.0%) patients; mean OS was 57.48 months with death occurring in two (4.9%) patients. Survival curves revealed TLG, MTV, and BRCA status as prognosticator for PFS; BRCA was also a prognosticator for OS. Univariate and multivariate analyses did not confirm such insights. Conclusion: We reported a correlation between some PET/CT parameters and BRCA status; some insights on their prognostic role have been underlined. Full article
(This article belongs to the Special Issue Advances of PET-CT Imaging in Oncology)
►▼ Show Figures

Figure 1

Other

Jump to: Research

4 pages, 879 KiB  
Case Report
High-Resolution Splenic Imaging: [68Ga]Ga-Oxine Red Blood Cell PET/CT for Differentiation of Splenosis Mimicking Malignant Lymphoma
by Anke Werner, Martin Freesmeyer and Robert Drescher
Tomography 2022, 8(6), 2915-2918; https://doi.org/10.3390/tomography8060244 - 12 Dec 2022
Cited by 1 | Viewed by 1423
Abstract
The differentiation of splenic tissue from malignant lesions via imaging may be challenging, particularly considering aberrant or accessory lesions and diseases that are rarely encountered. Functioning splenic tissue can be identified using technetium-99m red blood cell (99mTc-RBC) scintigraphy, but its sensitivity [...] Read more.
The differentiation of splenic tissue from malignant lesions via imaging may be challenging, particularly considering aberrant or accessory lesions and diseases that are rarely encountered. Functioning splenic tissue can be identified using technetium-99m red blood cell (99mTc-RBC) scintigraphy, but its sensitivity is limited and may not be available. We present the case of a patient in whom disseminated abdomino-pelvic splenosis was diagnosed using PET/CT with gallium-68-oxine-labeled RBCs. The method represents a feasible and probably superior alternative to splenic scintigraphy. Full article
(This article belongs to the Special Issue Advances of PET-CT Imaging in Oncology)
►▼ Show Figures

Figure 1

4 pages, 437 KiB  
Case Report
Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT
by Riccardo Laudicella, Flavia La Torre, Valerio Davì, Ludovica Crocè, Demetrio Aricò, Giuseppe Leonardi, Simona Russo, Fabio Minutoli, Irene A. Burger and Sergio Baldari
Tomography 2022, 8(5), 2471-2474; https://doi.org/10.3390/tomography8050205 - 30 Sep 2022
Cited by 6 | Viewed by 1561
Abstract
For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging technique by the European Association of Urology (EAU) guidelines is prostate-specific membrane antigen (PSMA) positron emission tomography/computer tomography (PET/CT). Indeed, the increased detection rate of PSMA PET/CT for early BCR has led [...] Read more.
For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging technique by the European Association of Urology (EAU) guidelines is prostate-specific membrane antigen (PSMA) positron emission tomography/computer tomography (PET/CT). Indeed, the increased detection rate of PSMA PET/CT for early BCR has led to a fast and wide acceptance of this novel technology. However, PCa is a very heterogeneous disease, not always easily assessable with the highly specific PSMA PET with around 10% of cases occuring without PSMA expression. In this paper, we present the case of a patient with PCa BCR that resulted negative on [68Ga]Ga-PSMA-11 PET/CT, but positive on [18F]Fluoromethylcholine (Choline) PET/CT. Full article
(This article belongs to the Special Issue Advances of PET-CT Imaging in Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop